A Multiattribute Model for Evaluating the Benefit-Risk Profiles of Treatment Alternatives
Authors:
- 1 January 2009
- journal article
- Published by SAGE Publications in Medical Decision Making
- Vol. 29 (1) , 104-115
Abstract
The assessment of the benefits and risks associated with a medicine's use requires careful consideration of a wealth of information of varying format and quality, ranging from efficacy and safety data derived from randomized clinical trials to statistical results from health outcomes studies to spontaneously reported adverse events. Contrary to the expectations of patients, physicians, and regulators, the literature offers little guidance as to how to strike an appropriate balance between benefit and risk. Although a qualitative listing of a medicine's benefits and risks is useful, much could be gained from a systematic and transparent process to evaluate a medicine's pre- and postmarketing performance. The authors propose a representational model based on multicriteria decision analysis that can incorporate both evaluative judgments from different perspectives (e.g., physician, patient) and quantitative data to inform tradeoffs between multiple benefit and multiple risk elements in a logically consistent and transparent manner. The model is designed to highlight the relative merits and deficits of treatment alternatives in well-defined and specific contexts. It is intended to serve as a common platform to facilitate focused benefit-risk tradeoff discussions between scientists, physicians, regulatory authorities, and pharmaceutical companies, and to assist in the communication of clear and consistent messages regarding those tradeoffs.Keywords
This publication has 15 references indexed in Scilit:
- Current Assessment of Risk–Benefit by Regulators: Is It Time to Introduce Decision Analyses?Clinical Pharmacology & Therapeutics, 2007
- A quantitative approach to benefit-risk assessment of medicines – part 1: the development of a new model using multi-criteria decision analysisPharmacoepidemiology and Drug Safety, 2007
- Palliative Care and the QALY ProblemHealth Care Analysis, 2005
- Benefit-Risk AnalysisDrug Safety, 2003
- Limitations of the Methods Used for Calculating Quality-Adjusted Life-Year ValuesPharmacoEconomics, 2002
- Cost-Value Analysis in Health Care1999
- Concepts in Risk-Benefit Assessment A Simple Merit Analysis of a Medicine?Drug Safety, 1996
- A new proposal for benefit-less-risk analysis in clinical trialsControlled Clinical Trials, 1994
- A multiple criteria decision analytic approach for evaluating acid rain policy choicesEuropean Journal of Operational Research, 1987
- A scale for assessing the severity of diseases and adverse drug reactions; Application to drug benefit and riskClinical Pharmacology & Therapeutics, 1979